{
    "nct_id": "NCT00909285",
    "title": "Testing the Effects of TMS Stimulation and Cognitive Training for Alzheimer Patients: A Pilot Study",
    "status": "COMPLETED",
    "last_update_time": "2010-07-11",
    "description_brief": "Current diagnosis of Alzheimer disease is made by clinical, neuropsychological, and neuroimaging assessments. Routine structural neuroimaging evaluation is based on nonspecific features, such as atrophy, which is a late feature in the progression of the disease. Therefore, developing new approaches for early and specific recognition of Alzheimer disease at the prodromal stages is of crucial importance.\n\nIn the present study the investigators would like to examine if combined treatment with TMS and cognitive training (CoTra) for several weeks can produce a sustained improvement in cognitive and behavioral symptomatology of Alzheimer's disease (AD) patients. A number of in vivo neuroimaging techniques, which can be used to reliably and noninvasively assess aspects of neuroanatomy, chemistry, physiology, and pathology, hold promise.",
    "description_detailed": "N/A",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention described is combined transcranial magnetic stimulation (TMS, a noninvasive neuromodulation device) plus cognitive training (CoTra) intended to produce sustained improvement in cognitive and behavioral symptoms in AD patients. This is an intervention aimed at improving cognition rather than a biologic or small-molecule therapy targeting AD pathology, so it best fits the 'cognitive enhancer' category. \ue200cite\ue202turn0search5\ue202turn0search0\ue201",
        "Act (key details extracted): The study tests TMS combined with cognitive training (often delivered as neuroAD\u2122 / NICE-System devices in similar trials) rather than an investigational drug; trial records and summaries identify Neuronix / neuroAD / NICE-System as the device used and label the study a pilot/early trial of rTMS + cognitive training (e.g., NCT01168245 / related pilot reports). No pharmacologic agent is specified in the provided description. \ue200cite\ue202turn0search5\ue202turn0search7\ue202turn0search2\ue201",
        "Supporting evidence from the literature: Multiple randomized and controlled trials and meta-analyses report cognitive benefits from rTMS combined with cognitive training or alone in MCI/AD, supporting the interpretation that this is a cognition\u2011enhancing neuromodulatory intervention (examples: an rTMS+COG RCT and a systematic review/meta\u2011analysis). \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Reflect: Although the description also mentions behavioral symptomatology (i.e., neuropsychiatric symptoms), the primary stated goal is sustained improvement in cognitive and behavioral symptomatology with a neuromodulation + training approach. That places the trial squarely in the 'cognitive enhancer' category (with possible secondary effects on neuropsychiatric symptoms). If you want the classification to emphasize behavior over cognition, an alternative label could be 'neuropsychiatric symptom improvement', but the text emphasizes cognitive improvement first. \ue200cite\ue202turn0search5\ue202turn0search0\ue201",
        "Web search results used (brief):\n- Trial summary / registry and study listing indicating TMS + cognitive training (neuroAD / NICE-System; Neuronix sponsor) and pilot design. \ue200cite\ue202turn0search5\ue202turn0search2\ue201\n- PubMed report of rTMS combined with cognitive training (rTMS-COG) showing cognitive improvements in AD. \ue200cite\ue202turn0search0\ue201\n- Large systematic review / meta-analysis showing overall cognitive benefits of TMS in MCI and AD populations. \ue200cite\ue202turn0search3\ue201"
    ],
    "agent_type": "M) Synaptic Plasticity/Neuroprotection",
    "explanation_agent": [
        "Reason: The intervention is noninvasive neuromodulation (TMS/rTMS) combined with cognitive training, intended to improve cognition by modifying neuronal activity and promoting adaptive plasticity rather than by acting on a specific molecular pathology (amyloid, tau, inflammation, etc.). This mechanism aligns best with CADRO's Synaptic Plasticity/Neuroprotection category.",
        "Act: Key details extracted from the description \u2014 intervention = transcranial magnetic stimulation (TMS/rTMS) + cognitive training (CoTra); no pharmacologic agent or molecular target specified; trial labeled a cognitive enhancer/pilot study. Based on these facts, assign 'M) Synaptic Plasticity/Neuroprotection'.",
        "Reflect: The classification was chosen because the primary therapeutic intent is to enhance cognition via neuromodulation-induced changes in neuronal excitability and plasticity. Alternative CADRO categories (e.g., D) Neurotransmitter Receptors) are less specific here because TMS does not target a single receptor or molecular pathway, and the trial is not diagnostic or non-therapeutic (so 'T) Other' is not appropriate). If future documentation showed a concurrent drug or a clear molecular target, the category should be reassessed (or 'R) Multi-target' if both device and drug targets are present).",
        "Web search results (user-provided / described): The user-supplied notes indicate registry/trial listings identifying TMS + cognitive training (neuroAD / NICE-System; Neuronix) as a pilot study, and cite RCTs and meta-analyses reporting cognitive benefits from rTMS \u00b1 cognitive training in MCI/AD \u2014 supporting that this is a cognition\u2011enhancing neuromodulatory intervention."
    ]
}